[The antimetabolites in isoimmunization caused by materno-fetal Rh blood group incompatibility].
D000328:Adult; D000963:Antimetabolites / Q000627:therapeutic use*; D001787:Blood Group Incompatibility / Q000188:drug therapy*; D004899:Erythroblastosis, Fetal / Q000188:drug therapy*; D005260:Female; D005419:Flavonoids / Q000627:therapeutic use; D005493:Folic Acid Antagonists / Q000627:therapeutic use; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn; D008727:Methotrexate / Q000627:therapeutic use; D011247:Pregnancy; D011687:Purines / Q000037:antagonists & inhibitors; D012204:Rh-Hr Blood-Group System
D000963:Antimetabolites; D005419:Flavonoids; D005493:Folic Acid Antagonists; D006634:Histamine H1 Antagonists; D011687:Purines; D012204:Rh-Hr Blood-Group System; D008727:Methotrexate
Gli antimetaboliti nella isoimmunizzazione da incompatibilità sanguigna materno-fetale al sistema Rh.